AIM: To measure the retinal function in retinal vein occlusion(RVO)combined with macular edemain patients treated with ranibizumab by using multifocal ERG(mfERG), and to analyze and evaluate the effects of ranibizumab treatment on macular edema.

METHODS:A retrospective, self-control method was used. Fifteen eyes of 15 patients who were clinically diagnosed as RVO with macular edema were included in this study. All patients were routinely corrected visual acuity, slit lamp microscopes, intraocular pressure, color fundus photography, FFA and OCT, the central 10° vision field, mfERG examination, corrected visual acuity using ETDRS visual acuity table. All patients were treated with intravitreal injection of ranibizumab 0.05mL/0.5mg and follow-up 3～12mo, including the monthly review once. The best corrected visual acuity, intraocular pressure, fundus, central macular thickness, central 10° vision field, the change of mfERG of these patients were observed. According to the referral, the repeated injection treatment was decided. The end of the follow-up was the time point to determine the efficacy, and the changes of vision field and mfERG in patients were recorded and analyzed.

RESULTS: The central visual field mean defect(MD)was significantly decreased at last follow-up(t=4.01, P<0.01). The 1^st and 2^nd ring N1 wave latency and the former P1 wave latency were significantly reduced(t=13.65, 16.31, P<0.01). The density values of P1 wave from treatment response in 1^st ring were significantly increased(t=7.78, P<0.01).

CONCLUSION: Intravitreal injection of ranibizumab treatment of macular edema secondary to venous occlusion can give a better prognosis and improve the sensitivity of patients' macular. The method of mfERG can accurately and objectively reflect the retinal function changes in patients with macular edema and could be potentially used in clinical.